PMID- 29439772
OWN - NLM
STAT- MEDLINE
DCOM- 20191029
LR  - 20211204
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 149
IP  - 4
DP  - 2018 Apr
TI  - Stomatitis associated with mammalian target of rapamycin inhibition: A review of 
      pathogenesis, prevention, treatment, and clinical implications for oral practice 
      in metastatic breast cancer.
PG  - 291-298
LID - S0002-8177(17)31019-X [pii]
LID - 10.1016/j.adaj.2017.10.024 [doi]
AB  - BACKGROUND: Patients with metastatic breast cancer may develop oral morbidities 
      that result from therapeutic interventions. Mammalian target of rapamycin (mTOR) 
      inhibitor-associated stomatitis (mIAS) is a common adverse event (AE), secondary 
      to mTOR inhibitor therapy, that can have a negative impact on treatment 
      adherence, quality of life, and health care costs. A multidisciplinary team 
      approach is important to minimize mIAS and to maximize treatment benefits to 
      patients with breast cancer. In this review, we discuss the pathophysiology, 
      diagnosis, and natural history of mIAS. Current and new management strategies for 
      the prevention and treatment of mIAS are described in the context of fostering a 
      coordinated team care approach to optimizing patient care. TYPES OF STUDIES 
      REVIEWED: The authors conducted a PubMed search from 2007 through 2017 using the 
      terms "stomatitis," "mIAS," "everolimus," "mTOR," "metastatic breast cancer," and 
      "oral care." They selected articles published in peer-reviewed journals that 
      reported controlled trials and evidence-based guidelines. RESULTS: mIAS can be 
      distinguished from mucositis caused by cytotoxic chemotherapy or radiotherapy on 
      the basis of cause, clinical presentation, and treatment paradigms. Specific 
      preventive and therapeutic management strategies can be implemented across the 
      continuum of patient oral health care. PRACTICAL IMPLICATIONS: Oral health care 
      providers are on the frontline of oral health care for patients with metastatic 
      breast cancer and are uniquely positioned to provide patient education, advocate 
      accurate reporting of mIAS, and support early identification, monitoring, and 
      prompt intervention to mitigate the severity and duration of this manageable, 
      potentially dose-limiting AE.
CI  - Copyright (c) 2018 American Dental Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Chambers, Mark S
AU  - Chambers MS
FAU - Rugo, Hope S
AU  - Rugo HS
FAU - Litton, Jennifer K
AU  - Litton JK
FAU - Meiller, Timothy F
AU  - Meiller TF
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180210
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Antineoplastic Agents
MH  - *Breast Neoplasms
MH  - Humans
MH  - Quality of Life
MH  - Sirolimus
MH  - *Stomatitis
MH  - TOR Serine-Threonine Kinases
OTO - NOTNLM
OT  - Stomatitis
OT  - aphthous stomatitis
OT  - dexamethasone mouthrinse
OT  - everolimus
OT  - mammalian target of rapamycin
OT  - mammalian target of rapamycin inhibitor-associated stomatitis
OT  - metastatic breast cancer
OT  - mucositis
OT  - sirolimus
OT  - temsirolimus
EDAT- 2018/02/15 06:00
MHDA- 2019/10/30 06:00
CRDT- 2018/02/15 06:00
PHST- 2017/05/03 00:00 [received]
PHST- 2017/10/06 00:00 [revised]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2019/10/30 06:00 [medline]
PHST- 2018/02/15 06:00 [entrez]
AID - S0002-8177(17)31019-X [pii]
AID - 10.1016/j.adaj.2017.10.024 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2018 Apr;149(4):291-298. doi: 10.1016/j.adaj.2017.10.024. Epub 
      2018 Feb 10.